AUTOLOGOUS LYMPHOCYTES PREVENT THE DEATH OF MONOCYTES IN CULTURE AND PROMOTE, AS DO GM-CSF, IL-3 AND M-CSF, THEIR DIFFERENTIATION INTO MACROPHAGES

被引:28
作者
LOPEZ, M
MARTINACHE, C
CANEPA, S
CHOKRI, M
SCOTTO, F
BARTHOLEYNS, J
机构
[1] CTR REG TRANSFUS SANGUINE,F-37 TOURS,FRANCE
[2] CTR NATL TRANSFUS SANGUINE,LES ULIS,FRANCE
[3] CTR DEPT TRANSFUS SANGUINE VAL MARNE,F-94 CRETEIL,FRANCE
关键词
ACTIVATED KILLER MACROPHAGE; MONONUCLEAR CELL; CULTURE; ADOPTIVE IMMUNOTHERAPY; GM-CSF; IL-3; M-CSF; IFN-GAMMA; RECOMBINANT HUMAN;
D O I
10.1016/0022-1759(93)90138-W
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Blood monocytes collected by apheresis from healthy donors were differentiated in vitro to macrophages which were subsequently activated with recombinant human interferon-gamma. 7 day cultures were established by seeding Ficoll-separated mononuclear cells or elutriation-purified monocytes under different culture conditions. The best macrophage yields required the seeding of mononuclear cells (instead of purified monocytes) in teflon bags with a high air-liquid surface interface. The effects of GM-CSF, IL-3 and M-CSF on the macrophage yield were then evaluated. GM-CSF increased the average yield by 3.6- and 2.3-fold when purified monocytes or total mononuclear cells were seeded respectively. The corresponding increases with IL-3 were 2.5- and 2.1-fold respectively and with M-CSF 1.2- and 1.4-fold respectively. Macrophages matured under these various conditions displayed similar CD14, CD64, CD71, HLA-DR and Max 1 antigen expression and similar in vitro anti-tumoral activity against U937 cells. Culturing in the presence of cytokines permits the large scale production of activated macrophages for adoptive immunotherapy trials.
引用
收藏
页码:29 / 38
页数:10
相关论文
共 12 条
  • [1] ANDREESEN R, 1990, CANCER RES, V50, P7450
  • [2] BARTHOLEYNS J, 1991, ANTICANCER RES, V11, P1201
  • [3] LONG-TERM CULTURES OF HUMAN MONOCYTES INVITRO - IMPACT OF GM-CSF ON SURVIVAL AND DIFFERENTIATION
    EISCHEN, A
    VINCENT, F
    BERGERAT, JP
    LOUIS, B
    FARADJI, A
    BOHBOT, A
    OBERLING, F
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1991, 143 (02) : 209 - 221
  • [4] FALK LA, 1988, J IMMUNOL, V140, P2652
  • [5] PHASE-I TRIAL OF INTRAVENOUS-INFUSION OF EXVIVO-ACTIVATED AUTOLOGOUS BLOOD-DERIVED MACROPHAGES IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER - TOXICITY AND IMMUNOMODULATORY EFFECTS
    FARADJI, A
    BOHBOT, A
    SCHMITTGOGUEL, M
    ROESLIN, N
    DUMONT, S
    WIESEL, ML
    LALLOT, C
    EBER, M
    BARTHOLEYNS, J
    POINDRON, P
    MORAND, G
    WITZ, JP
    OBERLING, F
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1991, 33 (05) : 319 - 326
  • [6] FISHER HG, 1988, J IMMUNOL, V141, P3882
  • [7] ADOPTIVE IMMUNOTHERAPY WITH ACTIVATED MACROPHAGES GROWN-INVITRO FROM BLOOD MONOCYTES IN CANCER-PATIENTS - A PILOT-STUDY
    LOPEZ, M
    FECHTENBAUM, J
    DAVID, B
    MARTINACHE, C
    CHOKRI, M
    CANEPA, S
    DEGRAMONT, A
    LOUVET, C
    GORIN, I
    MORTEL, O
    BARTHOLEYNS, J
    [J]. JOURNAL OF IMMUNOTHERAPY, 1992, 11 (03): : 209 - 217
  • [8] HUMAN-BONE MARROW PROCESSING IN VIEW OF FURTHER INVITRO TREATMENT AND CRYOPRESERVATION
    LOPEZ, M
    ANDREU, G
    BEAUJEAN, F
    EHRSAM, A
    GEROTA, J
    HERVE, P
    [J]. REVUE FRANCAISE DE TRANSFUSION ET IMMUNO-HEMATOLOGIE, 1985, 28 (05): : 411 - 426
  • [9] MANGAN DF, 1991, J IMMUNOL, V146, P1541
  • [10] NAKATA K, 1991, J IMMUNOL, V147, P1266